We analyzed the outcome of 108 adult acute lymphoblastic leukemia patients undergoing allogeneic bone marrow transplantation (BMT). Philadelphia (Ph) chromosome occurred in 35.2% patients at diagnosis. Two-thirds of patients received allogeneic BMT in first complete remission (CR1) BMT. Salvage BMT was performed in 21 and 16 patients at second complete remission (CR2) and beyond CR2. Donors were human leukocyte antigen-identical siblings in 87 patients, and match-unrelated donors in 21 patients. Conditioning contained total body irradiation (TBI) in 92.6% patients. Overall survival (OS) for BMT at CR1 and BMT beyond CR1 were 46.2 and 20.3% at 15 years. Multivariate analyses (including age, sex, disease status, donor type, acute graft-versus-host disease (aGVHD), stem cell source, cytogenetics, grade 1/2 aGVHD and TBI-containing conditioning regimen) identified ageo35, BMT at CR1 and grade 1/2 aGVHD as favorable factors for OS. Disease-free survival (DFS) for BMT at CR1 and beyond CR1 were 45.8 and 15.9% at 15 years, respectively, with BMT at CR1, ageo35 and grade 1/2 aGVHD being favorable factors for DFS. Importantly, conventional adverse risk factors such as the Ph chromosome, B-cell phenotype and high leukocyte count were not associated with inferior survivals. In summary, the adverse impact of Ph chromosome, B-cell phenotype and high leukocyte count was overcome by allogeneic BMT. Matched unrelated donor transplantation appears promising.
Introduction
Notable success has been achieved in the treatment of pediatric but not adult acute lymphoblastic leukemia (ALL) in recent decades. [1] [2] [3] [4] [5] For patients with human leukocyte antigen (HLA)-identical siblings, allogeneic bone marrow transplantation (BMT) offers another consolidation option, and is the best salvage for chemotherapy failures. 6, 7 Moreover, recent studies showed a promising outcome of allogeneic BMT with matched unrelated donors (MUD). 8 The analysis of prognostic factors in adult ALL patients undergoing allogeneic BMT has revealed certain important considerations. 9 Disease status is an important determinant of treatment-related mortality (TRM) and relapse rate, and thus ultimately survival. Moreover, the intensity of conditioning also impacts on both relapse rate and survival. While more intense conditioning regimens lead to better eradication of leukemic cells, they also result in more toxicity and higher mortality. This is further complicated by acute graft-versus-host disease (aGVHD). Active GVHD results in less disease relapse, owing to a putative graft-versus-leukemia (GVL) effect, but increases mortality related to complications from GVHD. Therefore, risk factors have to be analyzed for their impact on TRM, probability of relapse, relapsefree and overall survivals (OS). Finally, it is important to ascertain whether allogeneic BMT has overcome adverse prognostic factors inherent to the ALL, including high diagnostic leukocyte count, difficult remission, B-cell phenotype and presence of the Philadelphia (Ph) chromosome. 10, 11 Previous studies of allogeneic BMT either comprised a mixture of both adult and child patients, 12, 13 small number of patients 14 or short follow-up. 9 Here, we report the longterm outcome of allogeneic BMT in 108 adult ALL patients since 1990. To identify prognostic factors for survival, various risks were analyzed for their impact on relapse and survival in the whole group. This was followed by a further analysis in 71 ALL patients transplanted in first complete remission (CR1), in which other conventional adverse risk factors including age, diagnostic leukocyte count, leukemic cell phenotype and Ph chromosome status were also incorporated into the analysis.
Patients and methods

Patients
One hundred and eight consecutive adults (15-56 years old) with ALL receiving allogeneic BMT from January 1990 in Queen Mary Hospital (QMH) were included. QMH is the tertiary referral center for allogeneic BMT for adults in Hong Kong. In addition to patients with advanced disease, allogeneic BMT as consolidation in CR1 was offered to any adult ALL patients with an HLA-matched donor. When an HLA-matched sibling was not available, a search for a MUD would be initiated, and MUD BMT would be offered if an HLA-matched donor was identified. Although patients referred from other hospitals had not been treated with a uniform protocol, in general, all patients had received induction therapy comprising prednisolone, adriamycin, vincristine and L-asparaginase. In this cohort, allogeneic BMT was performed on 71 patients in CR1 as consolidation therapy, in which the definition of high-risk factors include: age435 years, white cell count (WCC; at diagnosis) 430 Â 10 9 /l, presence of the Ph chromosome and B-cell phenotype.
Preparative regimens, engraftment and aGVHD Conditioning regimens included Cy-TBI (cyclophosphamide: 120 mg/kg, total body irradiation: 12 Gy) (n ¼ 87), VP16-Cy-TBI (etoposide: 50 mg/kg, Cy: 100 mg/kg, TBI: 12 Gy) (n ¼ 13) and CBV (Cy ) (n ¼ 8). 15 Cyclosporine and short methotrexate were used for GVHD prophylaxis. Engraftment was defined as achievement of an absolute neutrophil count of X0.5 Â 10 9 /l for 3 consecutive days. aGVHD was diagnosed and graded according to standard criteria. 16 Statistics Disease-free survival (DFS) was measured from the date of BMT to the date of last follow-up, death or relapse. OS was measured from the date of BMT to the date of last followup or death. Cumulative probability of treatment-related mortality (TRM) was defined as death with no evidence of disease, and was measured from the time of BMT to the time of non-relapse death or last follow-up. Cumulative probability of relapse (Relapse) was measured from the time of BMT to the date of relapse or last follow-up. Survivals (DFS and OS), TRM and probability of relapse were plotted by the Kaplan-Meier method and compared by the log-rank test. For the whole group of 108 patients, potential prognostic factors impacting on DFS and OS such as age (p or 435 years), gender, karyotype (with or without Ph chromosome), disease status at BMT (CR1 and CR2 (second complete remission), untreated first relapse (UTR), refractory disease (RD)), donor type (HLA-identical sibling or MUD), stem cell source (bone marrow or peripheral stem cell), conditioning regimens (with or without TBI) and aGVHD (grade 1/2 versus grade 0/3/4) were analyzed by Cox's proportional hazard model (SPSS, Stepwise, Version 12.0, Chicago, IL, USA). 17, 18 For the 71 ALL patients transplanted at CR1, the above factors together with WCC at diagnosis (o30 Â 10 9 /l or 430 Â 10 9 /l) and phenotype (B-or T-cell lineage) were analyzed for their impact on DFS and OS. All P-values were two-sided.
Results
Clinical characteristics of the whole group of 108 patients Clinicopathologic features. The median age of the cohort was 33 years (range: 18-56 years). Cytogenetic study was successfully performed in 71 (65.7%) patients at diagnosis with the Ph þ chromosome found in 25 (35.2%) patients (Table 1) .
Treatment outcome for the whole group of patients Engraftment and aGVHD. All patients were successfully engrafted, at a median of 20 Probability of relapse. Of the whole group of 108 patients, 50 patients relapsed at a median of 7.6 months from the time of BMT. Thirty-five (70%) relapsed within the first year of BMT, 9 (18%) in the second year and 2 (4%) each in the third, fourth and fifth year from the date of BMT. Two patients developed local extramedullary leukemia relapse in the breast and sinus at 7 and 41 months after BMT. They were salvaged with intensive chemotherapy followed by peripheral stem cells from the same donor, and have remained disease-free 33.8 and 118.3 months from the date of BMT. Cumulative probability of relapse for the whole group was 58.8% at 15 years. Patients receiving stem cells from a MUD had a lower relapse rate than did HLA-matched sibling recipients (30.2 versus 64.3%, P ¼ 0.03). Moreover, presence of the Ph chromosome did not predict for a higher relapse rate compared with those without (P ¼ 0.63). To ascertain whether a MUD was associated with other risk factors for relapse, association between donor type and clinical characteristics was studied, which showed that MUD was associated with a higher frequency of grade 1/2 aGVHD, which occurred in 11 (52.4%) and 20 (22.9%) of patients receiving stem cells from MUD and matched siblings (P ¼ 0.01) ( Tables  1 and 2 ).
On multivariate analysis including age, sex, presence of the Ph chromosome, disease status, conditioning regimen, source of stem cells, aGVHD and donor type, MUD remained an independent factor predicting for a lower relapse rate (P ¼ 0.04, HR: 0.725; 95% CI: 0.533-0.987).
Disease-free and overall survivals. OS: The median followup time was 20.5 months (range: 1-195 months). Projected OS for the whole group was 35.3% at 15 years. The OS for BMT at CR1, CR2 and more advanced disease were 46.2, 29.4 and 9.4% (P ¼ 0.004). OS were 36.5% for patients with grade 0/1/2, and 27.5% for those with grade 3/4 aGVHD (P ¼ 0.15). OS were 43.3% for those with grade 0/1, and 29.8% for those with grade 2/3/4 aGVHD (P ¼ 0.29). On the other hand, OS for patients with grade 0, grade 1/2 and grade 3/4 aGVHD were 19.3, 54.1 and 27.1%, respectively (P ¼ 0.04) (Figure 1a ), suggesting that grade 1/2 aGVHD was a favorable form of aGVHD compared to other grades of aGVHD including grade 0 or grade 3/4 aGVHD. Indeed, OS for patients with grade 1/2 aGVHD and grade 0/3/4 aGVHD were 54.1 and 24.6% (P ¼ 0.01) (Figure 1b) . Therefore, grade 1/2 aGVHD was considered 'favorable' aGVHD and included as a risk factor on multivariate analysis. Patients with, and without the Ph chromosome had comparable projected OS (45.6 versus 46.7%, P ¼ 0.81). Univariate analysis showed advanced disease (beyond CR1) (P ¼ 0.004), 435 years of age (P ¼ 0.01) and grade 0/3/4 aGVHD (P ¼ 0.01) as adverse prognostic factors for OS. Moreover, on multivariate analysis including age, sex, presence of the Ph chromosome, disease status, conditioning regimen, source of stem cells, aGVHD and donor type, 435 years of age (Po0.01, HR: 2.341; 95% CI: 1.366-4.012), disease beyond CR1 (Po0.01, HR: 1.988; 95% CI: 1.412-2.799) and aGVHD of grade 0/3/4 (Po0.01, HR: 1.05; 95% CI: 1.019-1.082) remained as independent risk factors predicting inferior OS. Moreover, OS for patients with and without relapse were 5.7 and 72.1% (Po0.001) ( Table 1) .
DFS: Projected DFS for the whole group was 33.4% at 15 years. The DFS with BMT at CR1, CR2 and more advanced disease were 45.8, 23.9 and 6.2% (P ¼ 0.002) (Figure 2a ). DFS were 39.5% for patients with grade 0/1/2 (Figure 1c ), suggesting that grade 1/2 aGVHD was a favorable form of aGVHD compared to other grades (grades 0 or 3/4). Therefore, grade 1/2 aGVHD was considered 'favorable' aGVHD, and included as a risk factor in multivariate analysis. Univariate analysis showed that age 435 years (P ¼ 0.02), disease beyond CR1 (P ¼ 0.002), (Figure 2b ) 'unfavorable' aGVHD of grade 0/3/4 (P ¼ 0.01) (Figure 1d ) and HLAmatched sibling donor (P ¼ 0.03) ( Figure 2c) (Figure 2b ) and a trend toward increased probability of relapse (72.8 versus 51.3%, P ¼ 0.08). However, if comparison was restricted to those transplanted in CR1 (N ¼ 71) and CR2 (N ¼ 21), apart from a trend toward inferior DFS in patients transplanted at CR2 (P ¼ 0.08), there was no significant difference in TRM (P ¼ 0.23), relapse risk (P ¼ 0.18) and OS (P ¼ 0.24) ( Table 1) . aGVHD and survivals: There were 59, 10, 21, 12 and 6 patients with absent, grade 1, grade 2, grade 3 and grade 4 aGVHD. OS for patients with aGVHD of Xgrade 2 occurred in 32.2 and 52.3% patients receiving stem cells from HLA-matched siblings patients and MUDs (P ¼ 0.13).
Clinical characteristics and treatment outcome for the patients transplanted in CR1
Clinical characteristics of the 71 patients transplanted at CR1 are listed in Table 3 . Of these 71 patients, 56 (78.9%) had at least one of the conventional high-risk factors including age 435 years, initial WCC 430 Â 10 9 /l and poor-risk cytogenetics. If B-lineage is considered as a highrisk factor, then 66 (93%) patients had at least one highrisk factor (Table 3) .
The projected OS at 3, 5, 10 and 15 years were 58.9, 50.4, 46.2 and 46.2%, respectively, and the projected DFS at 3, 5, 10 and 15 years were 49.4, 45.8, 45.8 and 45.8%, respectively. Patients 435 years of age had an inferior OS (P ¼ 0.03) and DFS (P ¼ 0.01) at 15 years to those o35 years. On multivariate analysis including age, sex, B or T phenotype, WCC at diagnosis, presence of the Ph chromosome, conditioning regimen, source of stem cells, aGVHD and donor type, age 435 years remained an independent prognostic factor predicting inferior OS (P ¼ 0.03, HR: 2.439; 95% CI: 1.082-5.497) and DFS (Po0.01, HR: 2.809; 95% CI: 1.313-6.011).
Discussion
A number of factors were identified that favorably affected outcome after allogeneic BMT. First, age o35 years was associated with superior outcome, which might be related partly to a lower TRM. Similar results have been reported previously. 12, 14, [19] [20] [21] Second, we showed that allogeneic BMT in CR1 was associated with superior survivals. In a previous study of 182 adult ALL patients, Doney et al. 22 reported DFS of 43, 24 and 9% at 8 years for BMT in CR1, CR2 and relapse, which were comparable with our findings. Results from other reported studies were similar. 12, 14, [19] [20] [21] [22] However, we demonstrated that allogeneic BMT in 4CR2 or beyond was also associated with prolonged survivals in some patients, consistent with results reported previously. 6, 7 Furthermore, our findings showed that BMT in CR1 and CR2 were not significantly different, indicating that allogeneic BMT is a viable option in ALL patients achieving CR2.
About 50% of patients relapsed, the majority (70%) within the first year from BMT (median of 7.6 months). Literally all patients relapsing after BMT died shortly after relapse. On both univariate and multivariate analyses, the only factor associated with a lower relapse rate was MUD (probability of relapse was 64.3% with matched sibling donors and 30.2% with MUD, P ¼ 0.03). To see if patients receiving MUD transplants were associated with other risk factors, donor type was correlated with factors including age, sex, the Ph chromosome, disease status, conditioning, stem cell source and aGVHD. The other factor significantly associated with MUD was the higher frequency of 'favorable' grade 1/2 aGVHD (P ¼ 0.01). It is possible therefore that a more significant GVL effect was associated with MUD, resulting in a lower relapse rate. Moreover, in contrast to the conventional belief that a higher TRM might occur in BMT with MUD, our data showed that MUD was not associated with a higher TRM. Therefore, MUD is a viable option for adult patients with ALL in whom allogeneic BMT is indicated.
Moreover, apart from age, disease status at BMT and presence of aGVHD, relapse was, in fact, the most important risk factor for survival. Virtually, all those who relapsed died. Therefore, efforts should be focused on further reducing relapse rate. Recently, detection of minimal residual disease in ALL has been shown to have significant impact on relapse rate, 23 which may represent a good marker for pre-emptive treatment to prevent frank clinical relapse. Also, the role of post-BMT maintenance, similar to that used in patients receiving conventional ALL chemotherapy regimens, warrants further research as the majority (88%) of relapses occurred within the first 2 years. Despite this very gloomy prognosis of post-BMT relapse, two patients with isolated extramedullary relapse in the breast and sinuses at 7 and 41 months after BMT were successfully salvaged, and are surviving free of disease at 33.8 and 118.3 months after BMT. Ph-positive ALL is a high-risk ALL. We showed that the projected DFS was 33% in our cohort, which was comparable to 26-34% reported by others. 22, [24] [25] [26] Importantly, OS and DFS were comparable for patients with Ph-positive and Ph-negative ALL, owing to similar relapse rates. This implied that allogeneic BMT might overcome the adverse prognostic impact of the Ph chromosome. It remains to be determined whether the outcome may be further improved with optimal use of imatinib before and after BMT. 7 We showed that modest aGVHD of grade 1/2 had a favorable impact on DFS and OS. As GVHD has been associated with a putative GVL effect, 27, 28 the presence of GVHD is potentially important in the eradication or suppression of minimal residual disease. 29, 30 However, severe GVHD is associated with significant morbidity and even mortality, 21, 31 so that an optimum balance of GVHD has to be achieved. The association of mild aGVHD with superior DFS has also been reported in other studies. 19, 27 Last, subgroup analysis of patients receiving allogeneic BMT as consolidation in CR1 helped to address several questions. First, the results confirmed the adverse prognostic value of advanced age on survival, which was identified as an independent prognostic factor in the whole group. Second, apart from advanced age, other conventional high-risk factors for ALL, including high diagnostic leukocyte count, B-cell phenotype and presence of the Phchromosome, were no longer adverse prognostic factors after BMT. This suggested that BMT might have overcome these poor risk factors. However, while B-lineage ALL has been shown to convey a poor prognosis with inferior survivals including remission duration, 10, 32 recent ALL clinical trials incorporating intermediate-or high-dose methotrexate (1-3 g/m 2 ) or cytarabine (1 g/m 2 ) showed that the adverse prognostic impact of B-cell phenotype had been diminished or abolished. 33, 34 Our patients showed a projected OS that was similar to 44-57% reported in some studies, 20, 26, [35] [36] [37] [38] [39] but inferior to 61-75% in other studies. 33, 40, 41 Similarly, DFS was also comparable at 40-48% in some studies, 19, 20, 26, 37, 38 but inferior at 61-75% in others. 33, 40, 41 However, it is notable that studies reporting superior survivals comprised both adult and pediatric patients with a younger median age (24-25 years) than did our cohort. 40, 41 Finally, recent studies have shown superior survivals with BMT as consolidation compared to intensive chemotherapy for standard-risk ALL in CR1. 35, 33, 42 Moreover, as patients relapsing after conventional chemotherapy have a dismal prognosis (even if allogeneic BMT is available), 43 optimum treatment should be provided to prevent relapse. This may be achieved by allogeneic BMT as consolidation in adult ALL patients at CR1, which resulted in significantly higher OS than in those receiving conventional chemotherapy (54 versus 44%, Po0.05). 42 Indeed, our study also showed a comparable 5-year survival of 46% in adult ALL patients receiving an allograft in CR1, which was considerably higher than that seen in those receiving conventional chemotherapy (5-year OS: 13%), 44 thereby supporting the use of allogeneic BMT in CR1.
In conclusion, age o35 years, grade 1/2 aGVHD and CR1 BMT were favorable factors for survival. Allogeneic BMT benefits ALL patients in CR1 and those with advanced disease. Importantly, the conventional adverse impact of the Ph chromosome, B-cell phenotype and high WCC at diagnosis was overcome by allogeneic BMT. Obviously, the adverse prognostic impact of the Ph chromosome may be further improved with the use of imatinib in the future. The lack of excessive TRM after MUD transplantation suggests this to be a useful option in ALL patients without an HLA-identical sibling donor.
